Warfarin: An inconvenient truth

Stroke

Volumn 40, Issue 1, 2009, Pages 5-7

  Gattellari, Melina ^a,b,d   Worthington, John ^c   Zwar, Nicholas ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Centre for Research Evidence Management and Surveillance   (Australia)

^c Northern Beaches Stroke Service (JW)   (Australia)

^d Liverpool Health Service   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; IDRAPARINUX; PLACEBO; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DRUG CHOICE; DRUG SAFETY; DRUG USE; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; AGE; AGED; AGING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; CHEMICALLY INDUCED DISORDER; META ANALYSIS; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK ASSESSMENT; STATISTICS;

AGE FACTORS; AGED; AGING; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; HUMANS; INTRACRANIAL EMBOLISM; META-ANALYSIS AS TOPIC; RISK ASSESSMENT; STROKE; WARFARIN;

EID: 60549093415     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.527903     Document Type: Editorial

References (30)

1. Petersen P, Boysen G, Godfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for the prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;8631:175-179.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147:590-592.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
5. Gladstone DJ, Bui E, Fang B, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40: 235-240.
6. O'Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, Guyatt G, Gould L, D'Uva C, Kapral M, Silver F. Investigators of the Registry of the Canadian Stroke Network. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5: 749-754.
7. Allen LaPointe NM, Governale L, Watkins J, Mulgund J, Anstrom KJ. Outpatient use of anticoagulants, rate-controlling drugs, and antiar-rhythmic drugs for atrial fibrillation. Am Heart J. 2007;154:893-898.
8. Ansell J, Caro JJ, Salas M, Dolor RJ, Corbett W, Hundnut A, Seyal S, Lordan ND, Prooskorovsky I, Wygant G. Quality of clinical documentation and anticoagulation control in patients with chronic nonvalvular atrial fibrillation in routine medical care. Am J Med Qual. 2007;22: 327-333.
9. Falstaf Study Group, Leizorovicz A, Cohen A, Guenoun M, Mismetti P, Weisslinger N. Influence of age on the prescription of vitamin K antagonists in outpatients with permanent atrial fibrillation in France. Pharmacoepidemiol Drug Saf. 2007;16:32-38.
10. Lakshimarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general medicare population: a 10 year perspective. Stroke. 2006;37:1969 -1974.
11. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patients and hospital characteristics. Am J Med. 2006;119: 607-615.
12. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070-1074.
13. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E, BAFTA Investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
14. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM; Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust. 2004;181:492-497.
15. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S, Sandhar H, Hobbs FDR. Self management of oral anticoagulation: randomised trial. BMJ. 2005;331:1057-1062.
16. Connock M, Stevens C, Fry-Smith A, Jowett S, Fitzmaurice D, Moore D, Song F. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulant therapy: a systematic review and economic modelling. Health Technol Assess. 2007;11:iii-iv, ix-66.
17. Heneghan C, Alonso-Coello P, Gracia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367:404-411.
18. Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intra-cerebral hemorrhage. J Thromb Thrombolysis. 2008;25:26-32.
19. Progress Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
20. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
21. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
22. Lee WM. Larrey D, Olsson R, Lewis JH, Keisu M, Auclert L, Sheth S. Hepatic findings in long-term clinical trials of ximelagatran. Drug Safety. 2005;28:351-370.
23. The AMADEUS Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008; 371:315-321.
24. Turpie AGG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2007;29:155-165.
25. Ornstein SM, Jenkins RG, Nietert PJ, Feifer C, Roylance LF, Nemeth L, Corley S, Dickerson L, Bradford D, Litvin C. A multimethod quality improvement intervention to improve preventive cardiovascular care. A cluster randomized trial. Ann Intern Med. 2004;141:523-532.
26. Wright J, Bibby J, Eastham J, Harrison S, McGeorge M, Patterson C, Price N, Russell I, Small N, Walsh M, Young J. Multifaceted implementation of stroke prevention guidelines in primary care: cluster randomised evaluation of clinical and cost effectiveness. Qual Saf Health Care. 2007;16:51-59.
27. Thomson RG, Eccles MP, Steen IN, Greenaway J, Stobbart L, Murtagh MJ, May CR. A patient decision aid to support shared decision-making on antithrombotic treatment of patients with atrial fibrillation: a randomized controlled trial. Qual Saf Health Care. 2007;16:216-223.
28. McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson D, Majumdar SR, Gibson P, Cox JL, Fradette M. Impact of a patient decision aid on care among patients with non-valvular atrial fibrillation: a cluster randomised trial. CMAJ. 2005;173:496-501.
29. Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Norman SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ. 2006;332: 141-145.
30. Holbrook A, Labiris R, Goldsmith GH, Ota K, Harb S, Sebaldt RJ. Influence of decision-aids on patient preferences for anticoagulant therapy: a randomized trial. Can Med Assoc J. 2007;176:1583-1587.